L. Roy Papp & Associates LLP Has $20.33 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

L. Roy Papp & Associates LLP grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,150 shares of the medical research company’s stock after purchasing an additional 1,633 shares during the period. Thermo Fisher Scientific comprises approximately 2.4% of L. Roy Papp & Associates LLP’s holdings, making the stock its 12th biggest holding. L. Roy Papp & Associates LLP’s holdings in Thermo Fisher Scientific were worth $20,334,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Thermo Fisher Scientific by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company’s stock valued at $16,659,627,000 after buying an additional 230,382 shares during the last quarter. Amundi raised its holdings in Thermo Fisher Scientific by 5.9% during the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after purchasing an additional 168,197 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Thermo Fisher Scientific by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company’s stock worth $1,455,774,000 after purchasing an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company’s stock worth $1,432,816,000 after purchasing an additional 193,378 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after purchasing an additional 329,974 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $534.92 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a 50 day simple moving average of $487.44 and a 200 day simple moving average of $448.31. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The firm has a market capitalization of $201.99 billion, a PE ratio of 30.94, a P/E/G ratio of 2.91 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Analysts Set New Price Targets

TMO has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday. Weiss Ratings reissued a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Finally, William Blair initiated coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating for the company. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $593.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.